Precision Medicine

New data shows first-in-class drug tegavivint successfully inhibits the Wnt pathway, a driver in 30% of solid tumors, offering hope for tough cancers.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

At a landmark CMS event, Centauri, HealthEx, and Doctronic demo AI-powered apps promising a future where patient data is secure, accessible, and intelligent.

A new natural suppository aims to break the cycle of recurrent yeast infections by supporting the vaginal microbiome, offering hope to millions of women.

An exclusive partnership between Osmind and CareNet GPO gives small practices the power of large systems, aiming to broaden patient access to advanced mental healthcare.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

A new maternal blood test claims over 97% accuracy in predicting autism risk, offering hope for early intervention while igniting a fierce ethical debate.

With the hire of a top scientist, a minority-owned IT firm signals its ambition to tackle complex federal health challenges and compete with industry giants.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A new study reveals why GLP-1 drugs work for some and not others. 23andMe's research could personalize obesity treatment for millions of patients.

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.